Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Myriad Genetics Gets Rights To RAD51C Gene

RELATED NEWS
Trade MYGN now with 

Myriad Genetics, Inc. (MYGN: Quote) said Wednesday it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer.

In several studies, mutations in the RAD51C gene have been identified and associated with an increased risk for hereditary breast and ovarian cancer.

RAD51C was identified initially as a susceptibility gene for hereditary breast and ovarian cancer by members of the German Consortium for Hereditary Breast and Ovarian cancers in collaboration with pediatric hematologists and basic scientists predominantly located at the universities of Cologne, Dusseldorf and Munich.

Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C.

Click here to receive FREE breaking news email alerts for Myriad Genetics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections. Stocks are showing a lack of direction in early trading on Friday after ending the previous session sharply higher. The major averages have been bouncing back and forth across the unchanged line, unable to sustain any significant moves. While the Commerce Department released a report on Friday showing a modest increase in new home sales in the U.S. in the month of September, the uptick came from a significantly downwardly revised level in August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.